|
| View previous topic :: View next topic |
| Author |
Message |
ironjustice
Guest
|
 Posted: Sun Mar 02, 2008 3:02 pm Post subject: The Great Promise Of Iron Depletion |
 |
|
Summary
Expert Opinion on Therapeutic Patents
November 2006, Vol. 16, No. 11, Pages 1533-1556
(doi:10.1517/13543776.16.11.1533)
Iron chelators as therapeutic iron depletion agents
Noah Birch¯1, Xiang Wang¯1 & Hyun-Soon Chong¯1
1Chemistry Division, Biological, Chemical and Physical Sciences
Department,Illinois Institute of Technology, Chicago, IL 60616, USA.
Chong@iit.edu
† Author for correspondence
The great promise of iron depletion as a therapeutic strategy for
various diseases, including iron overload, cancers, Alzheimer’s
disease, Parkinson’s disease, tuberculosis, HIV, and fungal and
malaria infection, has stimulated research on the development of iron
chelators as iron depletion agents. In November 2005, the FDA approved
deferasirox (ICL670A; Exjade®), the first once-daily oral drug for
treatment of chronic iron overload. So far, five iron chelators,
deferoxamine, deferiprone, deferasirox, dexrazorane and ciclopirox,
have been approved for use in iron overload, anticancer or antifungal
therapy. Triapine® is in Phase I and II clinical trials for the
treatment of various metastatic and solid cancers. A desferrithiocin
analogue, deferitrin, is presently in a Phase I trial for the
treatment of iron overload diseases. Among the iron chelators being
evaluated in preclinical settings are the analogues of deferiprone,
pyridoxal isonicotinoyl hydrazone, desferrithiocin, deferoxamine,
thiosemicarbazone, tachpyridine, N,N'-bis(2-
hydroxybenzyl)ethylenediamine-N,N'-diacetic acid and hydroxyquinoline.
This review describes the comparative properties of iron chelators in
clinical use and evaluates the patent status of the novel synthetic
iron chelators in preclinical settings.
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com
Man Is A Herbivore!
http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk |
|
| Back to top |
|
 |
Google
Sponsor
|
| Posted: Sun Mar 02, 2008 3:02 pm Post subject: Advertisement |
|
|
|
|
| Back to top |
|
|
Guest
|
| Posted: Sun Mar 02, 2008 7:24 pm Post subject: Re: The Great Promise Of Iron Depletion |
|
|
On Mar 2, 10:02 am, ironjustice <teamtan...@hotmail.com> wrote:
| Quote: | Summary
Expert Opinion on Therapeutic Patents
November 2006, Vol. 16, No. 11, Pages 1533-1556
(doi:10.1517/13543776.16.11.1533)
Iron chelators as therapeutic iron depletion agents
Noah Birch 1, Xiang Wang 1 & Hyun-Soon Chong 1
1Chemistry Division, Biological, Chemical and Physical Sciences
Department,Illinois Institute of Technology, Chicago, IL 60616, USA.
Ch...@iit.edu
† Author for correspondence
The great promise of iron depletion as a therapeutic strategy for
various diseases, including iron overload, cancers, Alzheimer’s
disease, Parkinson’s disease, tuberculosis, HIV, and fungal and
malaria infection, has stimulated research on the development of iron
chelators as iron depletion agents. In November 2005, the FDA approved
deferasirox (ICL670A; Exjade®), the first once-daily oral drug for
treatment of chronic iron overload. So far, five iron chelators,
deferoxamine, deferiprone, deferasirox, dexrazorane and ciclopirox,
have been approved for use in iron overload, anticancer or antifungal
therapy. Triapine® is in Phase I and II clinical trials for the
treatment of various metastatic and solid cancers. A desferrithiocin
analogue, deferitrin, is presently in a Phase I trial for the
treatment of iron overload diseases. Among the iron chelators being
evaluated in preclinical settings are the analogues of deferiprone,
pyridoxal isonicotinoyl hydrazone, desferrithiocin, deferoxamine,
thiosemicarbazone, tachpyridine, N,N'-bis(2-
hydroxybenzyl)ethylenediamine-N,N'-diacetic acid and hydroxyquinoline.
This review describes the comparative properties of iron chelators in
clinical use and evaluates the patent status of the novel synthetic
iron chelators in preclinical settings.
Who loves ya.
Tom
Jesus Was A Vegetarian!http://jesuswasavegetarian.7h.com
Man Is A Herbivore!http://tinyurl.com/a3cc3
DEAD PEOPLE WALKINGhttp://tinyurl.com/zk9fk
|
Very intersting, but...
It seems to me that this is the usual medical quackery.
Spend millions defining a symptom.
Spend more millions developing a drug to treat the symptom.
Gain Billions using the new drug to treat the symptom.
Very profitable, but...what is the cause? Why not just eliminate the
cause of the symptom?
DrCee
You cannot secure nor restore health with pus or poisons. |
|
| Back to top |
|
|
Homenet
Guest
|
| Posted: Mon Mar 03, 2008 1:06 pm Post subject: Re: The Great Promise Of Iron Depletion |
|
|
On 2 Mar, 19:24, drcee...@insightbb.com wrote:
| Quote: | On Mar 2, 10:02 am, ironjustice <teamtan...@hotmail.com> wrote:
Summary
Expert Opinion on Therapeutic Patents
November 2006, Vol. 16, No. 11, Pages 1533-1556
(doi:10.1517/13543776.16.11.1533)
Iron chelators as therapeutic iron depletion agents
Noah Birch 1, Xiang Wang 1 & Hyun-Soon Chong 1
1Chemistry Division, Biological, Chemical and Physical Sciences
Department,Illinois Institute of Technology, Chicago, IL 60616, USA.
Ch...@iit.edu
† Author for correspondence
The great promise of iron depletion as a therapeutic strategy for
various diseases, including iron overload, cancers, Alzheimer’s
disease, Parkinson’s disease, tuberculosis, HIV, and fungal and
malaria infection, has stimulated research on the development of iron
chelators as iron depletion agents. In November 2005, the FDA approved
deferasirox (ICL670A; Exjade®), the first once-daily oral drug for
treatment of chronic iron overload. So far, five iron chelators,
deferoxamine, deferiprone, deferasirox, dexrazorane and ciclopirox,
have been approved for use in iron overload, anticancer or antifungal
therapy. Triapine® is in Phase I and II clinical trials for the
treatment of various metastatic and solid cancers. A desferrithiocin
analogue, deferitrin, is presently in a Phase I trial for the
treatment of iron overload diseases. Among the iron chelators being
evaluated in preclinical settings are the analogues of deferiprone,
pyridoxal isonicotinoyl hydrazone, desferrithiocin, deferoxamine,
thiosemicarbazone, tachpyridine, N,N'-bis(2-
hydroxybenzyl)ethylenediamine-N,N'-diacetic acid and hydroxyquinoline.
This review describes the comparative properties of iron chelators in
clinical use and evaluates the patent status of the novel synthetic
iron chelators in preclinical settings.
Who loves ya.
Tom
Jesus Was A Vegetarian!http://jesuswasavegetarian.7h.com
Man Is A Herbivore!http://tinyurl.com/a3cc3
DEAD PEOPLE WALKINGhttp://tinyurl.com/zk9fk
Very intersting, but...
It seems to me that this is the usual medical quackery.
Spend millions defining a symptom.
Spend more millions developing a drug to treat the symptom.
Gain Billions using the new drug to treat the symptom.
Very profitable, but...what is the cause? Why not just eliminate the
cause of the symptom?
DrCee
You cannot secure nor restore health with pus or poisons.
|
Agreed, seems like its being done the long way!
------------------------------------
http://mesothelioma.mypressonline.com/index.html - Information and
advice on Mesothelioma cancer |
|
| Back to top |
|
|
|
|
You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot vote in polls in this forum
|
|
|
